ANA OAKNIN

Has grant

Head of Gynecological Cancer Program

Hospital Universitari Vall d'Hebron

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ana Oaknin is the Head of the Gynecological Cancer Program at Hospital Universitari Vall d'Hebron in Spain. Her research focuses primarily on innovative treatments for ovarian and endometrial cancers, with significant contributions to the understanding and management of these conditions through recent publications. Her latest work includes studies on the efficacy of various therapies, including targeted treatments and immunotherapy, for recurrent ovarian cancer and novel insights into early-onset endometrial cancer.

Recent Grants

Grant: Close

Characterization of the Long-term Responders on Olaparib in Solid Tumours

Open Date: 2018-01-01

Close Date:

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

isabelle ray coquard

professor

FRANCE

View details

Rebecca S. Kristeleit

University of Arizona College of Medicine

UNITED STATES

View details

Jonathan Ledermann

University College London

UNITED KINGDOM

View details

Toon Van Gorp

Professor

Universitaire Ziekenhuizen Leuven

BELGIUM

View details

Cara Mathews

Assistant Professor

UNITED STATES

View details

Susana Banerjee

Reader in Women's Cancers (Systemic Therapy and Clinical Trials)

Institute of Cancer Research

UNITED KINGDOM

View details

Renaud Sabatier

Associate Professor

Aix-Marseille Université Faculté de Medecine

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ANA OAKNIN

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial

Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial

Molecular and clinical insights into early-onset endometrial cancer

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial

Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis

Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer

Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Reply to Z.R. McCaw et al

Collaborators (7)

isabelle ray coquard

Rebecca S. Kristeleit

Jonathan Ledermann

Toon Van Gorp

Cara Mathews

Susana Banerjee

Renaud Sabatier

Make your next move.